MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
NCT06171685
Age 18 - 99
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study is unique because it combines different therapies to see how well they work together. Here are some key points about the study:
- The treatment involves using a combination of medications that target the cancer cells in different ways.
- Patients will receive the treatment in a specific order to maximize its effectiveness.
- The study aims to find out if this combination can improve patient outcomes compared to standard treatments.
- Researchers will closely monitor patients for any side effects and overall health improvements.
- This approach is designed to be more personalized, taking into account individual patient responses to the treatment.
Third Opinion AI Generated Synopsis
Trial Summary
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol. The purpose of this proposed structure is to support the recurrent research challenge of efficiently evaluating what is the best therapy for a particular patient.
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol. The purpose of this proposed structure is to support the recurrent research challenge of efficiently evaluating what is the best therapy for a particular patient.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
